Shares of AngioDynamics ( ANGO -4.24%) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came ...

Q1 2025 Earnings Call Transcript October 3, 2024 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.11, ...

Throughout the last three months, 4 analysts have evaluated AngioDynamics ANGO -7.14% Get Free Report , offering a diverse ...

AngioDynamics (ANGO) stock falls 14% as the company misses estimates with its Q1 revenue, but beats on the bottom line. Read ...

AngioDynamics, Inc. ANGO reported an adjusted loss per share of 11 cents for first-quarter fiscal 2025, against the year-ago ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AngioDynamics (ANGO – Research Report) today and set a price target of $14.00.

Analysts expect the Latham, New York-based company to report a quarterly loss at 15 cents per share, versus a year-ago loss ...

Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

AngioDynamics expects full-year earnings in the range of 38 cents to 42 cents per share, with revenue in the range of $282 million to $288 million. AngioDynamics shares have decreased slightly more ...

AngioDynamics swung to a loss in its fiscal first quarter, although better than feared, and said it continues to expect sales growth in fiscal 2025.

Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued Radiofrequency ...

AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong ...